Home > Insider Trading > Filing (0000899243-18-020659)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1737953	Replimune Group Inc.	REPL	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1578965	Adam Koppel	C/O Bain Capital Life Sciences Investors 200 Clarendon Street Boston MA 02116	Yes	No	No	No
1687968	Bain Capital Life Sciences Fund, L.p.	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702921	Bcip Life Sciences Associates, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702957	Lawrence Jeffrey Schwartz	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703030	Bain Capital Life Sciences Partners, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-24	2,338,968	$0.00	2,338,968	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2018-07-24	500,000	$15.00	2,838,968	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-07-24	235,146	$0.00	2,338,968	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities").
The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date.
On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering.